Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience.
Soatti CP, Delishaj D, D'Amico R, Frigerio C, Fumagalli IC, Bonsignore F, Sangalli G, Declich F, Arcangeli S, Ardizzoia A, Colombo A. Soatti CP, et al. Among authors: ardizzoia a. J Contemp Brachytherapy. 2020 Dec;12(6):533-539. doi: 10.5114/jcb.2020.101685. Epub 2020 Dec 16. J Contemp Brachytherapy. 2020. PMID: 33437300 Free PMC article.
Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy: A review of literature.
Delishaj D, Fumagalli IC, Ursino S, Cristaudo A, Colangelo F, Stefanelli A, Alghisi A, De Nobili G, D'Amico R, Cocchi A, Ardizzoia A, Soatti CP. Delishaj D, et al. Among authors: ardizzoia a. World J Clin Cases. 2021 Oct 26;9(30):9077-9089. doi: 10.12998/wjcc.v9.i30.9077. World J Clin Cases. 2021. PMID: 34786390 Free PMC article.
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Galli L, Chiuri VE, Di Lorenzo G, Pisconti S, Rossetti S, Sirotova Z, Muto A, Petrioli R, De Tursi M, Sbrana A, Francolini G, Ardizzoia A, Scavelli C, Satta F, Quadrini S, Airoldi M, D'Aniello C, Bonetti A, Conforti S, Aieta M, Beccaglia P, Maestri A, Fratino L. Galli L, et al. Among authors: ardizzoia a. Tumori. 2023 Apr;109(2):224-232. doi: 10.1177/03008916221079662. Epub 2022 Apr 9. Tumori. 2023. PMID: 35400269 Free PMC article.
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group. Procopio G, et al. ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405438 Free PMC article.
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S. Vavalà T, et al. Among authors: ardizzoia a. Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26. Lung Cancer. 2016. PMID: 27040855 Free article.
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.
Steger GG, Dominguez A, Dobrovolskaya N, Giotta F, Tubiana-Mathieu N, Pecherstorfer M, Ardizzoia A, Blasinska-Morawiec M, Espinosa E, Villanova G. Steger GG, et al. Among authors: ardizzoia a. Clin Breast Cancer. 2018 Feb;18(1):e41-e47. doi: 10.1016/j.clbc.2017.05.012. Epub 2017 Jun 27. Clin Breast Cancer. 2018. PMID: 28666812 Clinical Trial.
Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.
Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M; Italian Association of Neuro-Oncology. Silvani A, et al. J Neurooncol. 2019 May;142(3):455-462. doi: 10.1007/s11060-019-03116-z. Epub 2019 Feb 6. J Neurooncol. 2019. PMID: 30726533 Clinical Trial.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Pignata S, et al. Among authors: ardizzoia a. Lancet Oncol. 2021 Feb;22(2):267-276. doi: 10.1016/S1470-2045(20)30637-9. Lancet Oncol. 2021. PMID: 33539744 Clinical Trial.
151 results